Abiopharma

METAGENOMI, INC. (MGX) Reports the reporting period Financial Results METAGENOMI, INC. (MGX) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: (257
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 120664
  • anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  • targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/. Cautionary Note Regarding Forward‐Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933